CMVLF Stock UPDATES Cellectis Romainvil (CMVLF) 14.7600 09/18/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 18, 2014 at 10:08 PM

Cellectis Romainvil (CMVLF) 14.7600 $CMVLF

Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:

Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:

Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:

Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014

Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.

Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.
Business Wire - Tue Jul 29, 1:04AM CDT
Regulatory News:

Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:

Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :

Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.

Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE

FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:

US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:

Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:

Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :

Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Depots, by Contributing Ectycell's Shares to Cellectis Bioresearch
Business Wire - Tue Jan 07, 11:00AM CST
Regulatory News:

Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
Business Wire - Thu Jul 04, 11:00AM CDT
Regulatory News:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRIMAX Poised to Meet AI-Driven Power Challenges

TRIMAX's Bold Move into AI-Powered Infrastructure It feels like we're standing on the cusp of a seismic shift, folks. Artificial intelligence isn't just another buzzword anymore—it's a juggernaut reshaping our digital world. TRIMAX Power Systems is gearing up to ride this wave, with its eyes set on capturing a chunk of the booming demand for fast-deployable power...

Hot Property Alert: Prime Storage Facility Sale in Texas

Investment Gold in Abilene's Storage Sector Diving headfirst into the world of bricks and mortar, the opportunity brewing over in Abilene, Texas, packs a potent punch for anyone keen on beefing up their real estate portfolio with a top-notch asset. We're talking about Spare Feet Self Storage, a slick, Class A self-storage facility, serving the cream of the crop in a...

GL1F Crypto: A Breakthrough in On-Chain AI for Crypto

The Dawn of On-Chain Machine Learning In a world where crypto folks often tout decentralization like it’s the holy grail, GenesisL1 is throwing open the doors to a new kind of crypto playground with GL1F Crypto. A decentralized on-chain AI studio? Sounds like sci-fi, but here we are—hands on the precipice of democratized machine learning in your browser. A Lab in...

Dan Brown Joins Guidewire: Big Moves in P&C Software

Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...

Christmas Injury Lawyers Unveils SC Knowledge Center

In the world of legal labyrinths, sometimes you just need a guiding light, especially following a car accident. That's where the freshly launched South Carolina Car Accident Law Knowledge Center steps in. It’s no magic wand, but Christmas Injury Lawyers are certainly trying to cut the chaos. This online hub covers more ground than a small library, boasting 40 guides...

Hiromi Asai's Akatsuki Shines at Paris Fashion Week

An Ode to Tradition Amid Modern Menswear From the bustling avenues of New York to the storied streets of Paris, Hiromi Asai is showcasing something that strikes a chord deep in the fashion industry's soul. Her Spring/Summer 2027 collection, "Akatsuki — Before the Dawn," takes its rare blend of age-old Japanese textile craftsmanship across the pond to the City of Light....

Event Industry Power 50 Voting Surge Ahead of Close

An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....

Indiana American Water's PFAS Credits Total $25.5M

Indiana American Water Dishes Out Big Buck Refunds Swing by Indiana American Water's latest move, and what do you see? A whopping $25.5 million in PFAS settlement credits being doled out to customers. That's right, this ain't your everyday water utility story—there's real money on the line here. Over four rounds of bill credits since November 2025, customers have seen...

ProClad Unveils Innovative Hybrid 2.0 Cookware

Revolutionizing Cookware: The Launch of Hybrid 2.0 Today, everyone's buzzing about ProClad's big reveal—the Hybrid 2.0 Pan. Now, before you roll those skeptical eyes, hear me out. This isn’t your average bit of kitchen fluff; it’s a heavyweight contender stepping into the everyday cooking ring. What they've done here is combine the muscle of stainless steel searing...

OMLYCLO Shakes Up U.S. Biologic Market as Key Player

Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...